Cytodyn Inc (CYDY)

[DonDonDonDon]

how is heeling one out of 4 that are S2C failing it’s trial

It doesn't heal 1 out of 4. That is the relative benefit, not the absolute benefit. Critical patients in the leronlimab arm had a 38% mortality. Critical patients in the placebo arm had a 47% mortality rate. 47% is 24% larger than 38% but it is an absolute benefit of 9%.

There were 62 critical patients. If 2 more placebo patients had survived, the placebo arm would have had a lower mortality percentage than the leronlimab arm. In other words, the mortality benefit is likely due to random luck.